Analysis of the reasons why Trientine is so expensive

Trientine (Trientine) is a key copper chelator used to treat Wilson's disease. Its high price is mainly due to many factors. First of all, as a rare disease drug, trientine belongs to the category of orphan drugs, and its research and development and production scale are relatively limited. Due to the small patient base, it is difficult for pharmaceutical companies to dilute costs through large-scale production, which results in high unit drug costs, which is reflected in the final selling price.

Secondly, the production process of trientine is complex and requires extremely high raw materials and quality control. Copper chelates need to be stable and of high purity, and the production process must comply with strict GMP (Good Manufacturing Practice) standards to ensure drug safety and efficacy. These high-standard production requirements increase manufacturing costs, especially the special formulation processes for rare disease drugs, making it difficult to significantly reduce prices.

Third, as a specialized drug for the treatment of Wilson's disease, trientine's clinical needs are highly specialized and market competition is relatively limited. Because there are fewer competing drugs and patients are highly dependent on them, pharmaceutical companies have strong pricing power. In addition, after drugs enter the market, they need to bear expensive registration and approval fees and continuous investment in clinical research, and these costs will eventually be passed on to drug prices.

Finally, the differences between domestic and foreign markets and the impact of medical insurance policies are also important reasons for the high prices. In some countries and regions, trientine has not yet been included in the medical insurance, and patients need to bear all the costs themselves; while in China, although it is on the market, it is not included in the medical insurance catalog, and patients pay a high proportion of themselves. At the same time, the high prices of German original drugs in the international market have also set an example for domestic pricing. In summary, the high price of trientine is the result of multiple factors. If production efficiency can be improved and the process of medical insurance inclusion can be accelerated in the future, it is expected to alleviate the financial pressure on patients.

Reference materials:https://www.drugs.com/